NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171)

Please sign and return to:

Stuart Wood, Technology Appraisal Administrator
Email: TACommB@nice.org.uk
Fax: +44 (0)20 7061 9830
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by **Myeloma UK** and consequently I will not be submitting a personal statement.

Name: JUDY DEWINTER

Signed: [redacted]

Date: 20.12.13